Avoro Capital Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,250,000	Closed	-$9.49M	–	36
2025 Q3	$9.49M	Sell	1,250,000 -3,250,000	-72%	-$27.1M	0.12%	28
2025 Q2	$40.3M	Sell	4,500,000 -4,200,000	-48%	-$39.1M	0.71%	25
2025 Q1	$65.3M	Sell	8,700,000 -3,165,000	-27%	-$25.5M	1.02%	20
2024 Q4	$89.2M	Hold	11,865,000	–	–	1.26%	21
2024 Q3	$90.2M	Sell	11,865,000 -705,000	-6%	-$5.36M	1.31%	19
2024 Q2	$77.7M	Sell	12,570,000 -480,000	-4%	-$2.65M	1.03%	24
2024 Q1	$66.3M	Hold	13,050,000	–	–	0.77%	28
2023 Q4	$78.2M	Buy	13,050,000 +1,500,000	+13%	+$8.69M	1.08%	21
2023 Q3	$81.8M	Sell	11,550,000 -505,000	-4%	-$3.63M	1.28%	17
2023 Q2	$84.9M	Buy	12,055,000 +1,635,000	+16%	+$13.1M	1.15%	20
2023 Q1	$86.9M	Buy	10,420,000 +1,370,000	+15%	+$13.2M	1.29%	19
2022 Q4	$104M	Hold	9,050,000	–	–	1.55%	16
2022 Q3	$114M	Buy	9,050,000 +2,550,000	+39%	+$32.8M	2.11%	13
2022 Q2	$68.8M	Buy	6,500,000 +4,625,000	+247%	+$47.7M	1.36%	17
2022 Q1	$30.5M	Buy	+1,875,000	New	+$30.1M	0.56%	28
2018 Q1	–	Sell	-340,821	Closed	-$1.67M	–	57
2017 Q4	$1.67M	Sell	340,821 -1,437,704	-81%	-$6.96M	0.11%	43
2017 Q3	$9.32M	Sell	1,778,525 -175,000	-9%	-$896K	0.73%	27
2017 Q2	$10.9M	Buy	1,953,525 +350,524	+22%	+$2.14M	1.38%	21
2017 Q1	$13.5M	Sell	1,603,001 -28,501	-2%	-$198K	1.72%	20
2016 Q4	$10.3M	Buy	1,631,502 +252,100	+18%	+$1.31M	2.09%	19
2016 Q3	$6.08M	Buy	+1,379,402	New	+$5.51M	1.08%	25